An interventional study of Multimodal Rehabilitation in Multidisciplinary Communication, sponsored by Clínica INEBIR. Active, not recruiting at 1 site in Spain. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-22.
Sponsored by Clínica INEBIR · Not applicable, Interventional, and Supportive care
Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.
Among the 42 studies in Endometriosis with a site in Spain, this one is the 11th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2025, is one of 18 with no phase, reaches primary completion later than 3 of the 14 other live ones, and was the 33rd registered.
920 studies on the registry are indexed under Endometriosis; 266 are open to participants now.
Browse Endometriosis studies →13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:
Francisco Algaba Chueca · Sites in Spain
Arafarma Group, S.A. · Sites in Spain
University of Seville · Sites in Spain
Fundacion Dexeus · Sites in Spain
Hospital Universitari de Bellvitge · Sites in Spain
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 176 Endometriosis studies recruiting now, 51 (29%) set no upper age limit and 123 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 126 is above the median of 67 across 540 interventional studies indexed under Endometriosis.
Median enrollment 90 across the 33 interventional studies, 70 across the 8 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 42 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Clínica INEBIR as lead sponsor.
Clínica INEBIR has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Endometriosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07270393Biogipuzkoa Health Research InstituteStudy of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis. | 2026-12-01 |
| NCT06955221Hospital Universitari de BellvitgeEffect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | 2026-12-31 |
| NCT06024109Aesculap AGPerformance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy | 2027-01 |
| NCT06876376Fundacion DexeusIntraoperative Ultrasound in Bowel Deep Endometriosis | 2027-02 |
| NCT07393958Arafarma Group, S.A.Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain. | 2027-08-01 |
Among the 42 studies in Endometriosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the impact of a multimodal rehabilitation programme on epigenetic biomarkers in blood, quality of life, sexual function and pelvic floor muscle strength and endurance in women with dyspareunia and endometriosis.
Introduction: Endometriosis is a benign gynaecological disease that affects approximately 10% of women of childbearing age, causing chronic pelvic pain and profound dyspareunia, which significantly impairs quality of life. This study aims to evaluate the impact of a multimodal rehabilitation programme on epigenetic biomarkers, quality of life, sexual function and muscle strength in women with dyspareunia and endometriosis.
Study Design: Pilot of Randomised controlled clinical trial according to CONSORT and TIDieR guidelines. The study will run from January 2025 to January 2026.
Inclusion criteria: Women between 18 and 55 years old, diagnosed with endometriosis with dyspareunia and chronic pelvic pain, with the ability to communicate in Spanish, and approval of their gynaecologist.
Exclusion criteria: Neurological, oncological, autoimmune or serious psychiatric diseases that prevent exercise or manual therapy.
Sample Size: 20 women diagnosed with dyspareunia and endometriosis, randomly divided into two groups: 10 in the intervention group and 10 in the control group.
Intervention: The intervention group will receive a multimodal rehabilitation programme including therapeutic exercise, health education and manual therapy. The control group will not receive this intervention.
Primary results: Measurements will be taken at four key points in time: baseline (T0), 2 months (T1), 6 months (T2) and 12 months (T3). To assess the effect of the intervention on miR-21 levels in saliva, quality of life (SF-36 questionnaire), sexual function (FSFI), pain, and pelvic floor muscle strength (measured with Oxford and Perfect scales).
Second Results: Measurement of systemic inflammation by CRP and IL-6, hormone levels (oestrogen and progesterone), stress and psychological well-being (HADS), muscle strength (EPI-NO), adherence to treatment and satisfaction with the intervention.
Ethics and Privacy: The study will have the approval of the Ethics Committee of the University of Pablo de Olavide, following the Declaration of Helsinki and Spanish regulations (Law 14/2007 on Biomedical Research). Participants will sign an informed consent form, and the data will be managed in accordance with the Spanish Data Protection Act (Law 3/2018).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will receive a multimodal rehabilitation programme including therapeutic exercise, health education and manual therapy.
Other: Multimodal Rehabilitation
The control group will not receive this intervention.
The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
miR-21
miR-21 levels in saliva
Time frame: 1 month
Quality of life
will be measured with the The Short Form-36 Health Survey (SF-36). A higher score indicates better health status.
Time frame: 1 month
Sexual Function
Will be measured with the Female Sexual Function Index (FSFI) questionnaire. A higher score indicates better sexual function.
Time frame: 1 month
Pelvic Floor Muscle Strength
Will be measured with Oxford and Perfect scale. A higher score indicates better Muscle Strength status.
Time frame: 1 month
Pain
Will be measured with Brief Pain Inventory (BPI) Questionnaire. A higher score indicates worse health status.
Time frame: 1 month
Systemic inflammation
Will be measured with polymerase chain reaction (PCR).
Time frame: 1 month
Hormone Levels
Will be measured with blood test.
Time frame: 1 month
Psychological condition
Will be measured with Hospital Anxiety and Depression Scale (HADS). A higher score indicates worse health status.
Time frame: 1 month
satisfaction with the intervention
Will be measured with MedRisk questionnaire. The MedRisk Instrument for Measuring Patient Satisfaction With Physical Therapy Care. A higher score indicates greater disability or more pain.
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.
Of 196 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 211 studies reached it within 25 months; a quarter within 13 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.